Walters Group holds 7.05M Zentalis Pharmaceuticals (NASDAQ: ZNTL)
Rhea-AI Filing Summary
Zentalis Pharmaceuticals filed an initial ownership report showing that The Walters Group directly holds 7,050,000 shares of the company’s common stock. Footnotes explain that William T. Walters and Susan B. Walters may be deemed to share voting and dispositive power over these shares through The Walters Group, but each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
The filing also notes that Zentalis entered into a Stock Purchase Agreement with Matrix Capital Master Fund, LP to repurchase 7,500,000 shares of its common stock, with the repurchase closing on December 15, 2025. As a result of this repurchase, the reporting persons are deemed to be 10% holders, and this status did not arise from any new acquisition of securities by them.
Positive
- None.
Negative
- None.
FAQ
How many Zentalis (ZNTL) shares does The Walters Group report on this Form 3?
The Walters Group reports direct beneficial ownership of 7,050,000 shares of Zentalis Pharmaceuticals common stock on this Form 3.
Why are Walters Group and related persons deemed 10% owners of Zentalis (ZNTL)?
They are deemed 10% owners because Zentalis repurchased 7,500,000 shares of its common stock from Matrix Capital Master Fund, LP, which changed ownership percentages and caused their holdings to cross the 10% threshold.
Did The Walters Group or the Walters individuals buy new Zentalis shares in this filing?
No new acquisitions by the reporting persons are described. The filing states that their 10% holder status is not the result of any acquisition of securities by the reporting persons.
Who legally holds the reported Zentalis (ZNTL) shares on this Form 3?
The footnotes state that the shares are held directly by The Walters Group. William T. Walters and Susan B. Walters may be deemed to share voting and dispositive power through The Walters Group.
Do the Walters reporting persons claim full beneficial ownership of the Zentalis shares?
No. Each reporting person disclaims Section 16 beneficial ownership of the reported shares, except to the extent of any pecuniary interest.
What transaction involving Matrix Capital is referenced in this Zentalis (ZNTL) Form 3?
Zentalis entered into a Stock Purchase Agreement with Matrix Capital Master Fund, LP to repurchase 7,500,000 shares of its common stock, with the repurchase closing on December 15, 2025.